GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvation Bio Inc (NYSE:NUVB) » Definitions » Other Current Assets

Nuvation Bio (Nuvation Bio) Other Current Assets : $3.01 Mil (As of Sep. 2021)


View and export this data going back to 2020. Start your Free Trial

What is Nuvation Bio Other Current Assets?

Nuvation Bio's other current assets for the quarter that ended in Sep. 2021 was $3.01 Mil.

Nuvation Bio's quarterly other current assets declined from Mar. 2021 ($5.14 Mil) to Jun. 2021 ($4.47 Mil) and declined from Jun. 2021 ($4.47 Mil) to Sep. 2021 ($3.01Mil).

Nuvation Bio's annual other current assets stayed the same from . 20 ($0.00 Mil) to . 20 ($0.00 Mil) increased from . 20 ($0.00 Mil) to Dec. 2020 ($0.34 Mil).


Nuvation Bio Other Current Assets Historical Data

The historical data trend for Nuvation Bio's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvation Bio Other Current Assets Chart

Nuvation Bio Annual Data
Trend Dec20 Dec21
Other Current Assets
0.34 3.64

Nuvation Bio Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Other Current Assets Get a 7-Day Free Trial 0.34 5.14 4.47 3.01 3.64

Nuvation Bio Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.


Nuvation Bio Other Current Assets Related Terms

Thank you for viewing the detailed overview of Nuvation Bio's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Nuvation Bio (Nuvation Bio) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
1500 Broadway, Suite 1401, New York, NY, USA, 10036
Nuvation Bio Inc is a biopharmaceutical company. The company is engaged in developing therapeutic candidates for the unmet needs in oncology. The firm operates in pharmaceutical, biotechnology and other related markets that develop small molecules and drug conjugates as treatments for cancer patients.